The Porphyrias, α1-Antitrypsin Deficiency, Cystic Fibrosis and Other Metabolic Diseases of the Liver

Comprehensive Clinical Hepatology

Volumn , Issue , 2006, Pages 369-396

  Bonkovsky, Herbert L ^a,b,c   Reichheld, James H ^d,e  

^a Medicine and Molecular Microbial and Structural Biology   (United States)

^b Dental Clinical Research Center   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^d LOWELL GENERAL HOSPITAL   (United States)

^e TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 44449112397     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-03675-7.50029-9     Document Type: Chapter

References (49)

1. Ghishan FK, Greene HL Inborn errors of metabolism that lead to permanent liver injury. The metabolic and molecular bases of inherited disease 1995, 1084-1137. McGraw Hill, New York. C. Scriver, W.S. Sly, A.L. Barton Childs (Eds.).
2. Anderson KE The porphyrias. Hepatology 2003, 291-346. WB Saunders, Philadelphia, An excellent overview of the porphyrias. 4th ed. D. Zakim, T.D. Boyer (Eds.).
3. Bonkovsky HL Porphyria cutanea tarda and hepatitis C. Viral Hepatitis Rev 1998, 4:75-95.
4. Bonkovsky HL, Healey JF, Lourie AN, et al. Intravenous heme-albumin in acute intermittent porphyria: Evidence for repletion of hepatic hemoproteins and regulatory heme pools. Am J Gastroenterol 1991, 86:1050-1056.
5. Bonkovsky HL, Banner BF, Lambrecht RW, et al. Iron in liver diseases other than hemochromatosis. Annals Int Med 2005, 16:65-82.
6. Do KD, Banner BF, Katz E, et al. Benefits of chronic plasmapheresis and intravenous heme-albumin in erythropoietic protoporphyria after orthotopic liver transplantation. Transplantation 2002, 73:469-472.
7. Gouya L, Puy H, Robreau AM, et al. The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wild type FECH. Nat Genet 2002, 30:27-28.
8. Hahn M, Bonkovsky HL Disorders of porphyrin metabolism. Diseases of the liver and bile ducts: a practical guide to diagnosis and treatment 1998, 249-272. Humana, Totowa. G. Wu, J. Israel (Eds.).
9. Reichheld JH, Katz E, Banner BF, et al. The value of intravenous heme-albumin and plasmapheresis in reducing postoperative complications of orthotopic liver transplantation for erythropoietic protoporphyria. Transplantation 1999, 67:922-928.
10. Waldenström J. Neurological symptoms caused by so-called acute porphyria. Acute Psychiatr Neurol 1939, 14:375.
11. Askari FK Molecular mechanism of hepatocellular injury in α-1-antitrypsin deficiency. Hepatology 1995, 21:1745-1747.
12. Carrell RW, Lomas DA alpha;-1-Antitrypsin deficiency - a model for conformational diseases. N Engl J Med 2002, 346:45-53. This is a complete and intriguing review of the disease, in the context of clinically diverse but etiologically similar diseases.
13. Carrell RW, Whisstock J, Lomas DA Conformational changes in serpins and the mechanism of α-1-antitrypsin deficiency. Am J Respir Crit Care Med. Am J Respir Crit Care Med 1995, 151:926-1175. (Published erratum appears in:.).
14. Francavilla R, Castellaneta SP, Hadzic N, et al. Prognosis of α-1-antitrypsin deficiency-related liver disease in the era of paediatric liver transplantation. J Hepatol 2000, 32:986-992.
15. Perlmutter DH Clinical manifestations of α-1-antitrypsin deficiency. Gastroenterol Clin North Am 1995, 24:27-43.
16. Perlmutter DH Liver injury in α-1-antitrypsin deficiency: an aggregated protein induces mitochondrial injury. J Clin Invest 2002, 110:1579-1583.
17. Rudnick DA, Liao Y, An JK, et al. Analyses of hepatocellular proliferation in a mouse model of α-1-antitrypsin deficiency. Hepatology 2004, 39:1048-1055.
18. Colombo C, Crosignani A, Assaisso M, et al. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study. Hepatology 1992, 16:924-930.
19. Colombo C, Battezzati PM, Crosignani A, et al. Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. Hepatology 2002, 36:1374-1382.
20. Feranchak AP, Sokol RJ Cholangiocyte biology and cystic fibrosis liver disease. Semin Liver Dis 2001, 21:471-488. A detailed and updated review of the molecular biology of cystic fibrosis and its liver-specific histopathology, clinical features, diagnosis and management.
21. Nousia-Arvanitakis S, Fotoulaki M, Economou H, et al. Long-term prospective study of the effect of ursodeoxycholic acid on cystic fibrosis-related liver disease. J Clin Gastroenterol 2001, 32:324-328.
22. Slieker MG, Deckers-Kocken JM, Uiterwaal CS, et al. Risk factors for the development of cystic fibrosis related liver disease. Hepatology 2003, 38:775-776. author reply 776-777.
23. Tanner MS, Taylor CJ Liver disease in cystic fibrosis. Arch Dis Child 1995, 72:281-284.
24. Yang Y, Raper SE, Cohn JA, et al. An approach for treating the hepatobiliary disease of cystic fibrosis by somatic gene transfer. Proc Natl Acad Sci USA 1993, 90:4601-4605.
25. Gibbs TC, Payan J, Brett EM, et al. Peripheral neuropathy as the presenting feature of tyrosinaemia type I and effectively treated with an inhibitor of 4-hydroxyphenylpyruvate dioxygenase. J Neurol Neurosurg Psychiatry 1993, 56:1129-1132.
26. Holme E, Lindstedt S. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). J Inherit Metab Dis 1998, 21:507-517.
27. Kvittingen EA, Rootwelt H, Berger R, et al. Self-induced correction of the genetic defect in tyrosinemia type I. J Clin Invest 1994, 94:1657-1661.
28. Laine J, Salo MK, Krogerus L, et al. The nephropathy of type I tyrosinemia after liver transplantation. Pediatr Res 1995, 37:640-645.
29. Mohan N, McKiernan P, Preece MA, et al. Indications and outcome of liver transplantation in tyrosinaemia type 1. Eur J Pediatr 1999, 158:S49-S54.
30. Overturf K, Al-Dhalimy M, Tanguay R, et al. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nat Genet 1996, 12:266-273.
31. Poudrier J, Lettre F, Scriver CR, et al. Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes. Mol Genet Metab 1998, 64:119-125.
32. Russo PA, Mitchell GA, Tanguay RM Tyrosinemia: a review. Pediatr Dev Pathol 2001, 4:212-221. An excellent, recent review on tyrosinemia.
33. Krivit W, Freese D, Chan KW, et al. Wolman's disease: a review of treatment with bone marrow transplantation and considerations for the future. Bone Marrow Transplant 1992, 10(suppl 1):97-101.
34. Leone L, Ippoliti PF, Antonicelli R. Use of simvastatin plus cholestyramine in the treatment of lysosomal acid lipase deficiency. J Pediatr 1991, 119:1008-1009.
35. Wolman M. Wolman disease and its treatment. Clin Pediatr 1995, 34:207-212.
36. Cox TM Aldolase B and fructose intolerance. FASEB J 1994, 8:62-71.
37. Tolan DR Molecular basis of hereditary fructose intolerance: mutations and polymorphisms in the human aldolase B gene. Hum Mutat 1995, 6:210-218.
38. Bianchi L. Glycogen storage disease I and hepatocellular tumours. Eur J Pediatr 1993, 152(suppl 1):S63-S70.
39. Lei KJ, Chen YT, Chen H, et al. Genetic basis of glycogen storage disease type 1a: Prevalent mutations at the glucose-6-phosphatase locus. Am J Hum Genet 1995, 57:766-771.
40. Talente GM, Coleman RA, Alter C, et al. Glycogen storage disease in adults. Ann Intern Med 1994, 120:218-226.
41. Beutler E Galactosemia. Screening and diagnosis. Clin Biochem 1991, 24:293-300.
42. Holton JB Effects of galactosemia in utero. Eur J Pediatr 1995, 154:S77-S81.
43. Sardharwalla IB, Wraith JE Galactosaemia. Nutr Health 1987, 5:175-188.
44. Resnick JM, Whitley CB, Leonard AS, et al. Light and electron microscopic features of the liver in mucopolysaccharidosis. Hum Pathol 1994, 25:276-286.
45. Wraith JE The mucopolysaccharidoses: a clinical review and guide to management. Arch Dis Child 1995, 72:263-267.
46. Balicki D, Beutler E. Gaucher disease. Medicine 1995, 74:305-323. A thorough review on Gaucher disease.
47. Brady RO, Murray GJ, Barton NW Modifying exogenous glucocerebrosidase for effective replacement therapy in Gaucher disease. J Inherit Metab Dis 1994, 17:510-519.
48. Current issues in diagnosis and treatment. NIH Technology Assessment Panel on Gaucher Disease. JAMA 1996, 275:548-553. Gaucher disease.
49. Rosenthal DI, Doppelt SH, Mankin HJ, et al. Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics 1995, 96:629-637.